Arcus Biosciences Inc (RCUS)

Payables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cost of revenue (ttm)	US$ in thousands	146,000	147,000	147,000	145,000	122,000	119,374	115,668	113,504	106,935	102,117	92,166	83,156	74,346	63,355	58,189	52,795	44,024	37,906	35,287	30,566
Payables	US$ in thousands	18,000	13,000	15,000	16,000	17,000	17,000	12,000	28,000	20,000	10,546	21,984	18,094	10,000	13,219	16,957	24,544	15,682	8,102	12,052	2,426
Payables turnover		8.11	11.31	9.80	9.06	7.18	7.02	9.64	4.05	5.35	9.68	4.19	4.60	7.43	4.79	3.43	2.15	2.81	4.68	2.93	12.60

December 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $146,000K ÷ $18,000K
= 8.11

The payables turnover ratio for Arcus Biosciences Inc has fluctuated over the periods presented, ranging from a low of 2.15 to a high of 12.60. The ratio indicates how efficiently the company is managing its accounts payable by measuring the number of times a company pays off its average accounts payable balance during a specific period.

A higher payables turnover ratio suggests that the company is paying its suppliers more quickly, which can indicate strong cash flow management. Conversely, a lower ratio may indicate that the company is taking longer to pay its suppliers or may be facing liquidity issues.

Analyzing the trend of Arcus Biosciences Inc payables turnover, we observe fluctuations in the ratio, indicating potential changes in the company's payment policies or the way it manages its accounts payable. It is important for investors and analysts to carefully monitor this ratio to assess the efficiency of Arcus Biosciences Inc's accounts payable management and its impact on the company's overall financial health.